 |
ZIOPHARM Oncology to Present at the 38th Annual Deutsche Bank Health Care Conference
May 22, 2013
|
12.5 KB |
|
| |
BOSTON, May 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 38th Annual Deutsche Bank Health Care Conference on Wednesday, May 29th, 2013 at 8:00 a.m. ET at the Westin Boston Waterfront Hotel in Boston, Massachusetts.
To access a li...
|
|
ZIOPHARM Announces Presentation of Promising Nonclinical and Phase I Study Results of Ad-RTS-IL-12 in Advanced Melanoma at ASGCT 16th Annual Meeting
May 16, 2013
|
51.0 KB |
|
| |
BOSTON, May 16, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced promising results from nonclinical and Phase 1 studies in advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Findings were presented in an oral session at the 16th Annual Meeting of the American Society of Gene and Cell Therapy...
|
|
ZIOPHARM Announces Poster Presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting
May 15, 2013
|
49.9 KB |
|
| |
BOSTON, May 15, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Gerald P. Linette, MD, PhD, of the Washington University School of Medicine, will present updated clinical results from a Phase 1 study of Ad-RTS-hIL-12, a novel DNA-based therapeutic candidate in advanced melanoma at the 2013 American Society for Cl...
|
|
ZIOPHARM Announces First Quarter Financial Results and Key Developments
May 7, 2013
|
17.7 KB |
|
| |
BOSTON, May 7, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2013, and provided an update on the Company's key developments.
ZIOPHARM reported a GAAP net loss of $12.8 million for the first quarter of 2013, or $(0.15) per share, compared to a GAAP net loss ...
|
|
ZIOPHARM Presents Preclinical Data Supporting DNA-Based IL-12 Therapy for Breast Cancer
Apr 9, 2013
|
14.4 KB |
|
| |
NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of results from a study in a breast cancer murine model demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12, a vi...
|
|
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
Mar 26, 2013
|
15.6 KB |
|
| |
Restructuring to Place Exclusive Strategic Focus on Synthetic Biology ProgramsCompany to Host Conference Call Today, March 26, 2013 at 8:30 AM ET
NEW YORK, March 26, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced toda...
|
|
ZIOPHARM Reports Fourth Quarter and Full Year 2012 Financial Results
Mar 18, 2013
|
58.1 KB |
|
| |
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today its financial results for the fourth quarter and full year ending December 31, 2012, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.Fourth Quarter Results
The Company reported a GAAP net loss of $30.2 ...
|
|
ZIOPHARM Oncology Initiates Phase 2 Study of Ad-RTS IL-12 and Palifosfamide Combination for Treatment of Advanced Breast Cancer
Mar 11, 2013
|
13.9 KB |
|
| |
NEW YORK, March 11, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the initiation of a randomized, open label Phase 2 clinical study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resec...
|
|
ZIOPHARM Oncology to Present at the Barclays Global Healthcare Conference
Mar 7, 2013
|
12.4 KB |
|
| |
NEW YORK, March 7, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 4:15 p.m. ET at the Loews Hotel in Miami, Florida.
To access a live webcast of the presentation, pl...
|
|
ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors
Mar 6, 2013
|
60.3 KB |
|
| |
NEW YORK, March 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) in patients with recurrent metastatic germ cel...
|
|
Phase 3 Trial of ZIOPHARM'S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events
Feb 12, 2013
|
12.9 KB |
|
| |
NEW YORK, Feb. 12, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-control...
|
|
ZIOPHARM Oncology to Present at the 15th Annual BIO CEO & Investor Conference
Feb 6, 2013
|
12.7 KB |
|
| |
NEW YORK, Feb. 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 10:00 a.m. ET at the Waldorf Astoria in New York City.
To access a live webcast of the presenta...
|
|
ZIOPHARM Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference
Jan 3, 2013
|
12.7 KB |
|
| |
NEW YORK, Jan. 3, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 2:30 p.m. PT at the Westin St. Francis Hotel in San Francisco, CA.
To access a live webcast...
|
|
ZIOPHARM Oncology to Participate in the 2012 Deutsche Bank BioFEST Conference
Nov 28, 2012
|
12.4 KB |
|
| |
NEW YORK, Nov. 28, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 2012 Deutsche Bank BioFEST Conference on Tuesday, December 4, 2012 at 11:20 a.m. ET at the Four Seasons Hotel in Boston, MA.
To access a live webcast of the presentation...
|
|
ZIOPHARM Oncology to Present at the 24th Annual Piper Jaffray Healthcare Conference
Nov 20, 2012
|
12.7 KB |
|
| |
NEW YORK, Nov. 20, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012, at 1:30 p.m. EST at The New York Palace Hotel in New York City.
Dr. Lewis will provide an ...
|
|
Independent Data Monitoring Committee Recommends Completion of PICASSO 3 Trial as Conducted for ZIOPHARM's Palifosfamide in First-Line Soft Tissue Sarcoma
Nov 14, 2012
|
14.0 KB |
|
| |
- Independent Committee Concludes Progression-Free Survival Data From PICASSO 3 Trial Projected in First Quarter of 2013 -- Company to Host Update Call at 5:00 PM EST Today -
NEW YORK, Nov. 14, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new canc...
|
|
ZIOPHARM Announces Third Quarter Financial Results and Key Developments
Nov 8, 2012
|
18.5 KB |
|
| |
NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the third quarter ended September 30, 2012, and provided an update on the Company's key development activities.
The Company reported a GAAP net loss of $17.8 million for the third quarter of 2012, or $(0.23) per share, compared...
|
|
ZIOPHARM Oncology Presents Systemic, DNA/Cell Plasmid Therapy Showing Long-Term Persistence and Anti-Tumor Effects at EORTC-NCI-AACR Meeting
Nov 7, 2012
|
51.4 KB |
|
| |
NEW YORK, Nov. 7, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today results from a preclinical study demonstrating the long-term persistence and anti-tumor effects of a new synthetic biology approach (DNA/cell plasmi...
|
|
ZIOPHARM Oncology Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase 2 Study
Oct 25, 2012
|
14.3 KB |
|
| |
NEW YORK, Oct. 25, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that compelling clinical activity was seen in its Phase 1 study of Ad-RTS IL-12, a novel DNA-based therapeutic candidate, in advanced melanoma. Based...
|
|
ZIOPHARM Issues Statement Regarding Misleading Blog
Oct 19, 2012
|
8.5 KB |
|
| |
NEW YORK, Oct. 19, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding a blog entry posted by Richard Pearson, Contributor, on Forbes.com:
"The statements made in Mr. Pearson's blog entry are misleading and wrong and, given his disclosed investment position, we call into question the ent...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
